Business Wire

Alvarez & Marsal Appoints Four New Managing Directors in Its Paris Office

Del

Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of four Paris-based Managing Directors, Jonathan Gibbons, Guillaume Martinez, Frederic Steiner and Donatien Chenu, to the firm’s Global Transaction Advisory Group. These appointments advance A&M’s strategic expansion plans to meet local market demand in France, enhance its cross-border M&A offering and help clients address increasingly complex regional, European and global regulatory requirements.

The addition of Messrs. Gibbons, Martinez, Steiner and Chenu, all formerly with one of the Big Four in France, completes the latest phase of A&M’s European strategic growth plan following the launch of the firm’s Stockholm office and Nordics expansion in 2017 that added to existing transaction advisory activities in the U.K., Germany, and Netherlands. They will bolster A&M’s suite of integrated global transaction advisory services that provide clients with a differentiated offering for due diligence and transaction advisory requirements.

A&M’s market share continues to expand with the firm’s European practices experiencing strong growth over the past two years leading to work on a range of flagship European private equity deals. With A&M’s operational focus and market leading capabilities in Private Equity and Corporate Performance Improvement, A&M is uniquely placed to provide a differentiated approach to due diligence and take on the challenges of current market conditions faced by clients.

Antonio "Tony" Alvarez III, Managing Director and A&M’s European Practice lead, said, “These appointments support our global expansion strategy along with our capability building plans in France and Europe. New audit regulation and rotation rules are impacting the provision of non-audit services and generating greater conflicts in providing those services to clients. As growing numbers of Big Four professionals across Europe look beyond the traditional firms, A&M’s platform is acknowledged to be less restrictive enabling greater access for practice growth.”

Paul Aversano, Managing Director and Global Practice Leader of A&M’s Global Transaction Advisory Group, said, “The growth of our transaction advisory presence in France supports the firm’s commitment to meet local market needs and global market M&A demands with our unique and differentiated approach. These appointments are the latest of several growth areas in France and Europe for A&M to enable us to continue our European expansion.”

Managing Director and European Practice Lead with A&M’s Transaction Advisory Group, David Evans, added, “Jonathan’s, Guillaume’s, Frederic’s, and Donatien’s in-depth knowledge advances our ability to help private equity firms and corporate clients maximize value on a pan-European basis. We expect the French team to grow rapidly as client needs continue to escalate.”

Tarek Hosni, the France country leader and Managing Director with A&M Paris, stated, “The addition of these senior transaction professionals will enable us to increase our scale and service for French private equity firms as well as France based multinationals. A leading protagonist of positive transformation in France, we now also intend to deliver in France our internationally recognized expertise in transaction advisory services. This marks the start of our future growth plans for A&M France.”

A&M’s new Transaction Advisory Managing Directors have extensive cross-border and global transaction experience working with private equity and multi-national corporations throughout Europe and the world. The team’s collective experience spans numerous sectors including TMT, manufacturing, retail and consumer goods and financial services. For more information on Messrs. Gibbons, Martinez, Steiner and Chenu, please click on the links to their bios below:

Jonathan Gibbons

Guillaume Martinez

Frederic Steiner

Donatien Chenu

About Alvarez & Marsal

Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) when conventional approaches are not enough to make change and achieve results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services.

With over 3000 people across four continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, help organizations transform operations, catapult growth and accelerate results through decisive action. Comprised of experienced operators, world-class consultants, former regulators and industry authorities, A&M leverages its restructuring heritage to turn change into a strategic business asset, manage risk and unlock value at every stage of growth.

When action matters, find us at alvarezandmarsal.com. Follow A&M on LinkedInTwitter and Facebook.

Note to Editor:

About Alvarez & Marsal Global Transaction Advisory Group

A&M’s Global Transaction Advisory Group provides investors and lenders the answers needed to get the deal done. We combine our firm’s deep operational, industry and functional resources with Big Four-quality financial accounting and tax expertise to assess key deal drivers and focus on the root cause of any critical deal issues. As the largest transaction advisory practice outside the Big Four, our global integrated teams help private equity, sovereign wealth funds, family offices and hedge funds as well as corporate acquirers unlock value across the investment lifecycle.

The firm’s Global Transaction Advisory Group includes over 350 professionals in 22 offices throughout the U.S., Latin America, Europe, India and Asia. Our global team has extensive industry knowledge across multiple sectors including, but not limited to, dedicated industry verticals in healthcare, software & technology, energy and financial services.

Contact information

Alvarez & Marsal
Helene Willberg, +46 70 589 9763
Managing Director
or
Sandra Sokoloff, +1 212-763-9853
Senior Director of Global Public Relations
or
Margaret Cameron-Waller, +44 (0)207 7155202
Director of Marketing U.K. & Europe

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00Pressemelding

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00Pressemelding

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27Pressemelding

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00Pressemelding

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 10:11Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 10:06Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo